Supernus Pharmaceuticals to Participate in March Investor Conferences
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) said management will participate in three March 2026 investor conferences: TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), and Barclays Global Healthcare (March 11).
Webcasts: TD Cowen and Barclays sessions will be webcast and archived for 60 days on the company website; investors should contact conference coordinators to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction – SUPN
In the Feb 24 session, SUPN gained 5.15%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date notice | Neutral | -2.9% | Announced timing of Q4 and full-year 2025 results and conference call. |
| Dec 09 | Regulatory approval | Positive | -3.7% | Health Canada authorization for ZURZUVAE for postpartum depression treatment. |
| Dec 03 | Conference participation | Neutral | +0.2% | Participation in Bank of America 2025 CNS Therapeutics Virtual Conference. |
| Nov 21 | Conference participation | Neutral | -0.4% | Participation in Piper Sandler 37th Annual Healthcare Conference fireside chat. |
| Nov 12 | Conference participation | Neutral | -0.4% | Planned fireside chat at 2025 Jefferies Global Healthcare Conference in London. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference and event-related announcements have typically led to modest price moves, with no strong or consistent reaction pattern evident around such calendar updates.
Over the last several months, Supernus has regularly updated investors on conference participation and key dates, including a Q4 and full year 2025 results call on Feb 24, 2026. Prior conference notices in November and December 2025 produced small price moves between about -0.4% and +0.22%. Today’s March conference schedule fits this pattern of standard investor-relations outreach rather than a major new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:
| TD Cowen 46th Annual Health Care Conference | |
| Date: Fireside chat: Place: Webcast Link: | Monday, March 2, 2026 2:30 p.m. ET Boston Marriott Copley Place, Boston, Mass. Here |
| Jefferies Biotech on the Beach Summit | |
| Date: Place: | Tuesday, March 10, 2026 1 Hotel South Beach, Miami Beach, Fla. |
| Barclays 28th Annual Global Healthcare Conference | |
| Date: Fireside chat: Place: Webcast Link: | Wednesday, March 11, 2026 2:00 p.m. ET Loews Miami Beach, Miami Beach, Fla. Here |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live audio webcast of the TD Cowen and Barclays Conference presentations can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of these webcasts will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
